Drug Trial Radar · NCT01148849
Safety Study of MGAH22 in HER2-positive Carcinomas
Last checked: Nov 20, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Jul 2010
Primary completion
Jun 14, 2022
Study completion Jun 14, 2022
Sponsor
- Lead sponsor
- MacroGenicsIndustry
- Sponsor type
- Industry
- Collaborators
- Green Cross Corporation; National Cancer Institute (NCI)
- First posted
- Jun 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if MGAH22 is safe when given by intravenous (IV) infusion to patients with HER2-positive cancer. The study will also evaluate how long MGAH22 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it has an effect on tumors.
Conditions
- Breast Cancer
- Gastric Cancer
Interventions
margetuximabBiological
margetuximab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Adverse Events and Serious Adverse EventsTime frame: Up to 28 days after last infusion
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
National Cancer Institute
Bethesda, Maryland
Sarah Cannon Research Institute
Nashville, Tennessee
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.